Alligator Bioscience: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 monthsBiomarker analysis confirms immune activatio ...
Aptevo Therapeutics: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...
MarketWatch18h
E-Mini S&P 500 Future Continuous Contract
2-Year U.S. Treasury Note Continuous Contract $102.734-0.035-0.03% 5-Year U.S. Treasury Note Continuous Contract $106.891-0.117-0.11% 10-Year U.S. Treasury Note Continuous Contract $110.078-0.203 ...
MarketWatch17h
Crude Oil WTI (NYM $/bbl) Front Month
2-Year U.S. Treasury Note Continuous Contract $102.730-0.039-0.04% 5-Year U.S. Treasury Note Continuous Contract $106.883-0.125-0.12% 10-Year U.S. Treasury Note Continuous Contract $110.063-0.219 ...
BBC14h
Market Data
From the end of November Market data will no longer be displayed here.